Chugai Pharmaceutical Co. Ltd. | Ownership
Companies that own Chugai Pharmaceutical Co. Ltd.
Wellington Management Co. LLP
16,715,106
2.99%
30,088
0.18%
07/31/2018
Nomura Asset Management Co., Ltd.
15,379,997
2.75%
110,430
0.5%
07/31/2018
Nikko Asset Management Co., Ltd.
7,562,587
1.35%
381,187
0.26%
09/03/2018
Daiwa Asset Management Co. Ltd.
6,776,900
1.21%
198,200
0.45%
07/31/2018
Capital Research & Management Co. (World Investors)
5,818,000
1.04%
0
0.05%
06/30/2018
The Vanguard Group, Inc.
5,381,002
0.96%
40,700
0.01%
07/31/2018
BlackRock Fund Advisors
4,039,700
0.72%
6,200
0.01%
09/06/2018
Mitsubishi UFJ Kokusai Asset Management Co., Ltd.
3,587,422
0.64%
70,922
0.44%
07/31/2018
Norges Bank Investment Management
2,490,817
0.45%
-823,724
0.02%
12/31/2017
T. Rowe Price International Ltd.
2,164,300
0.39%
-53,700
0.23%
06/30/2018
| Address |
Nihonbashi Mitsui Tower, 15/F
Tokyo Tokyo 103
Japan
|
|
Employees
|
- |
| Website |
http://www.chugai-pharm.co.jp |
| Updated |
07/08/2019 |
| Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of the pharmaceuticals. Its operations are carried out through the following business divisions: Research, Development, Production, Marketing, Medical Affairs and Drug Safety. The Research division focuses its efforts on creating innovative drugs by using its competitive strengths that include proprietary antibody technologies and cutting-edge research resources. |
